Table 2.

Disease-modifying anti-rheumatic drugs (DMARDs) used during the 10 years of follow-up

DMARD	No (%) of patients	Mean time (months) ± SD
Methotrexate	86 (76.7%)	63.0 ± 39.2
Sulfasalazine	58 (51.7%)	44.7 ± 42.6
Methotrexate + sulfasalazine	33 (29.4%)	37.7 ± 33.9
Gold salts	33 (29.4%)	23.2 ± 24.0
Hydroxychloroquine	24 (21.4%)	20.6 ± 17.5
Leflunomide	24 (21.4%)	20.7 ± 18.2
D-penicillamine	2 (1.7%)	23.4 ± 23.2
Ciclosporin	4 (3.5%)	23.0 ± 23.3
Etanercept	12 (10.7%)	16.7 ± 18.3
Infliximab	9 (8.0%)	19.4 ± 7.0
Adalimumab	4 (3.5%)	15.4 ± 18.7
Anakinra	1 (0.8%)	8.9
Abatacept	1 (0.8%)	2.1